Literature DB >> 23913135

Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.

Almut G Winterstein1.   

Abstract

The past decade has seen a heated debate over the cardiac safety of central nervous system stimulants in the treatment of ADHD. This review discusses five controlled population-based studies that investigated this risk in children in the United States. All studies utilized administrative claims data of private or public insurance to compare risk of stimulant use to non-use. Two studies with smaller sample size lacked the ability to investigate serious events but report a slightly increased risk of emergency department visits attributed to cardiac symptoms such as tachycardia or palpitation. Three studies that enrolled more than one million patients found no association between stimulants and composite endpoints of sudden cardiac death, myocardial infarction, stroke and ventricular arrhythmia. The studies concur that background rates of serious cardiovascular events in children are extremely small. No study exceeded an average follow-up of two years, prohibiting inferences about long-term effects of stimulants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913135     DOI: 10.1007/s11920-013-0379-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  17 in total

1.  A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Eric Mick; Craig Surman; Robert Doyle; Paul Hammerness; Theresa Harpold; Stephanie Dunkel; Meghan Dougherty; Megan Aleardi; Thomas Spencer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

2.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

3.  Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

Authors:  Almut Gertrud Winterstein; Tobias Gerhard; Jonathan Shuster; Arwa Saidi
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

4.  Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

Authors:  Richard H Weisler; Joseph Biederman; Thomas J Spencer; Timothy E Wilens
Journal:  CNS Spectr       Date:  2005-12       Impact factor: 3.790

5.  Cardiovascular events and death in children exposed and unexposed to ADHD agents.

Authors:  Hedi Schelleman; Warren B Bilker; Brian L Strom; Stephen E Kimmel; Craig Newcomb; James P Guevara; Gregory W Daniel; Mark J Cziraky; Sean Hennessy
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

6.  ADHD drugs and serious cardiovascular events in children and young adults.

Authors:  William O Cooper; Laurel A Habel; Colin M Sox; K Arnold Chan; Patrick G Arbogast; T Craig Cheetham; Katherine T Murray; Virginia P Quinn; C Michael Stein; S Todd Callahan; Bruce H Fireman; Frank A Fish; Howard S Kirshner; Anne O'Duffy; Frederick A Connell; Wayne A Ray
Journal:  N Engl J Med       Date:  2011-11-01       Impact factor: 91.245

7.  [Tachycardia-induced cardiomyopathy in children: a difficult diagnosis but a reversible form of left ventricular dysfunction].

Authors:  M El Hajjar; J S Hermida; F M Caron; D Nassif; E Bourges-Petit; Y Maingourd
Journal:  Arch Pediatr       Date:  2004-01       Impact factor: 1.180

8.  24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy.

Authors:  Cindy D Stowe; Stephanie F Gardner; Charles C Gist; Eldon G Schulz; Thomas G Wells
Journal:  Ann Pharmacother       Date:  2002 Jul-Aug       Impact factor: 3.154

9.  Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Almut G Winterstein; Tobias Gerhard; Jonathan Shuster; Michael Johnson; Julie M Zito; Arwa Saidi
Journal:  Pediatrics       Date:  2007-12       Impact factor: 7.124

10.  Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.

Authors:  Almut G Winterstein; Tobias Gerhard; Paul Kubilis; Arwa Saidi; Stephan Linden; Stephen Crystal; Julie Zito; Jonathan J Shuster; Mark Olfson
Journal:  BMJ       Date:  2012-07-18
View more
  6 in total

Review 1.  Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

Authors:  Gariba A H Awudu; Frank M C Besag
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

2.  Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases.

Authors:  William P Cheshire
Journal:  Clin Auton Res       Date:  2016-03-11       Impact factor: 4.435

Review 3.  Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.

Authors:  Jose Martinez-Raga; Amparo Ferreros; Carlos Knecht; Raquel de Alvaro; Eloisa Carabal
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

Review 4.  A systematic review of the safety of lisdexamfetamine dimesylate.

Authors:  David R Coghill; Beatriz Caballero; Shaw Sorooshian; Richard Civil
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

Review 5.  ADHD and adolescent athletes.

Authors:  Ahsan Nazeer; Miriam Mansour; Kathleen A Gross
Journal:  Front Public Health       Date:  2014-06-17

6.  Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.

Authors:  David R Coghill; Tobias Banaschewski; Peter Nagy; Isabel Hernández Otero; César Soutullo; Brian Yan; Beatriz Caballero; Alessandro Zuddas
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.